阿达木单抗治疗化脓性汗腺炎与银屑病的严重感染风险比较
这项回顾性队列研究利用MarketScan数据库,纳入2017年1月至2020年12月启动阿达木单抗治疗的成人化脓性汗腺炎(HS)或银屑病患者,比较非皮肤感染住院风险。加权Cox分析显示HS组严重感染风险升高(HR 1.53,95%CI 1.34-1.86),且脓毒症和泌尿生殖道感染发生率及住院时间延长风险均高于银屑病组。
要点
- 阿达木单抗治疗的HS患者严重感染风险高于银屑病患者(HR 1.53)。
- HS组脓毒症和泌尿生殖道感染发生率显著更高。
- HS组住院时间延长的风险也高于银屑病组。
核心结论
- 在接受阿达木单抗治疗的成人中,中重度HS患者较银屑病患者有更高的感染风险和不同的感染谱。
主要发现
- 加权Cox分析显示HS组严重感染风险增加(HR 1.53,95%CI 1.34-1.86)。
- HS组脓毒症发生率比(IRR)为2.07(95%CI 1.35-3.12),泌尿生殖道感染IRR为2.22(95%CI 1.22-3.86)。
- HS组住院时间延长的比值比(OR)为1.28(95%CI 1.13-1.45)。
临床怎么用
- 临床对接受阿达木单抗治疗的HS患者应加强感染监测,尤其关注脓毒症和泌尿生殖道感染。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Previous research suggests that patients with hidradenitis suppurativa (HS) may face a higher risk of serious infections compared with those with psoriasis. However, these studies are subject to limitations that could constrain their reliability. OBJECTIVE: To compare the risk of hospitalization from noncutaneous infections, infection profiles, and the length of stay (LOS) of adult patients with HS and psoriasis treated with adalimumab. DESIGN, SETTING, AND PARTICIPANTS: This retrospective cohort study was conducted using deidentified claims data from the MarketScan database. All adult patients with HS or psoriasis who initiated adalimumab therapy between January 2017 and December 2020 were included. Data were analyzed from October 2023 to March 2024. EXPOSURES: New users of adalimumab diagnosed with psoriasis or HS, identified using International Statistical Classification of Diseases and Related Health Problems, Tenth Revision codes and adalimumab prescriptions. MAIN OUTCOMES AND MEASURES: The primary outcome was hospitalization from noncutaneous infections in a time-to-event analysis using inverse probability weighting to account for confounders in the Cox regression models. Secondary outcomes included the infection types compared using incidence rate ratios and LOS analyzed with multivariable Poisson regression. RESULTS: Of 10 349 included patients, 5641 (54.5%) were female, and the mean (SD) age was 44.8 (12.8) years. The cohort included 1650 patients with HS and 8699 with psoriasis. The HS cohort was younger (mean [SD] age, 36.2 [11.5] years vs 46.5 [12.4] years) and predominantly female (1271 [77.0%] vs 4370 [50.2%]), with higher rates of obesity, Crohn disease, anxiety, and depression. The weighted Cox analysis indicated an increased risk of serious infection in patients with HS (hazard ratio, 1.53; 95% CI, 1.34-1.86). This group also had a higher likelihood of sepsis and genitourinary infections (sepsis: incidence rate ratio, 2.07; 95% CI, 1.35-3.12; genitourinary infections: incidence rate ratio, 2.22; 95% CI, 1.22-3.86) and greater odds of prolonged LOS (odds ratio, 1.28; 95% CI, 1.13-1.45) compared with the psoriasis cohort. CONCLUSIONS AND RELEVANCE: In this cohort study, among adults treated with adalimumab, those with moderate to severe HS had an elevated risk of infection and different infection profiles compared with those with psoriasis. Future research should focus on the impacts of disease severity and treatment regimens on infection risk and develop targeted prevention strategies.
引用
- Wafae BGO, Charrow AP, Stein D, et al. Risk of Serious Infection With Adalimumab in Hidradenitis Suppurativa Compared With Psoriasis. JAMA Dermatol. 2025. PMID: 40833768. doi:10.1001/jamadermatol.2025.2881
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。